JP2018529320A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529320A5 JP2018529320A5 JP2018505723A JP2018505723A JP2018529320A5 JP 2018529320 A5 JP2018529320 A5 JP 2018529320A5 JP 2018505723 A JP2018505723 A JP 2018505723A JP 2018505723 A JP2018505723 A JP 2018505723A JP 2018529320 A5 JP2018529320 A5 JP 2018529320A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- cell
- cancer
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 56
- 206010028980 Neoplasm Diseases 0.000 claims 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 16
- 239000013604 expression vector Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 210000001519 tissue Anatomy 0.000 claims 14
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 13
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 11
- 108091008874 T cell receptors Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000005847 immunogenicity Effects 0.000 claims 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 238000010195 expression analysis Methods 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 3
- 238000002659 cell therapy Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 238000012163 sequencing technique Methods 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 108010028930 invariant chain Proteins 0.000 claims 2
- 239000012931 lyophilized formulation Substances 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000002493 microarray Methods 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000005934 immune activation Effects 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000716 merkel cell Anatomy 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940038309 personalized vaccine Drugs 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 238000012070 whole genome sequencing analysis Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201289P | 2015-08-05 | 2015-08-05 | |
| US62/201,289 | 2015-08-05 | ||
| GBGB1513921.5A GB201513921D0 (en) | 2015-08-05 | 2015-08-06 | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB1513921.5 | 2015-08-06 | ||
| PCT/EP2016/068727 WO2017021527A2 (en) | 2015-08-05 | 2016-08-05 | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191407A Division JP7142957B2 (ja) | 2015-08-05 | 2020-11-18 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529320A JP2018529320A (ja) | 2018-10-11 |
| JP2018529320A5 true JP2018529320A5 (enExample) | 2019-09-12 |
| JP6884752B2 JP6884752B2 (ja) | 2021-06-09 |
Family
ID=54200350
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505723A Active JP6884752B2 (ja) | 2015-08-05 | 2016-08-05 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020191407A Active JP7142957B2 (ja) | 2015-08-05 | 2020-11-18 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2022142129A Pending JP2022191218A (ja) | 2015-08-05 | 2022-09-07 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2024215091A Pending JP2025038025A (ja) | 2015-08-05 | 2024-12-10 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191407A Active JP7142957B2 (ja) | 2015-08-05 | 2020-11-18 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2022142129A Pending JP2022191218A (ja) | 2015-08-05 | 2022-09-07 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2024215091A Pending JP2025038025A (ja) | 2015-08-05 | 2024-12-10 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Country Status (36)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2508923A (en) * | 2012-12-17 | 2014-06-18 | Bombardier Transp Gmbh | Inductive power transfer system having inductive sensing array |
| HRP20192262T1 (hr) | 2013-08-05 | 2020-03-06 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc) |
| PE20231843A1 (es) | 2015-08-05 | 2023-11-21 | Eisai Randd Man Co Ltd | Reactivos quirales para la preparacion de oligomeros homogeneos |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| MY198087A (en) | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| CN108601731A (zh) | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP3635000A4 (en) * | 2017-05-16 | 2021-04-14 | The Johns Hopkins University | Manabodies and methods of using |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| ES2871146T3 (es) | 2017-07-14 | 2021-10-28 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| JP7470640B2 (ja) | 2018-02-09 | 2024-04-18 | イマティクス ユーエス，アイエヌシー． | Ｔ細胞を製造する方法 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| CA3136405A1 (en) * | 2018-06-01 | 2019-12-05 | Geneoscopy, Inc. | Detection method for cancer using rna biomarkers |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| US11945850B2 (en) * | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| US20220127313A1 (en) * | 2019-02-12 | 2022-04-28 | Vanderbilt University | Polypeptides for restoring endothelial function and methods of use thereof |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| PH12021552979A1 (en) | 2019-05-27 | 2023-10-09 | Immatics Us Inc | Viral vectors and their use in adoptive cellular therapy |
| US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| MX2022010461A (es) | 2020-02-24 | 2022-12-13 | Immatics Us Inc | Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas. |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| JP2023521219A (ja) * | 2020-04-14 | 2023-05-23 | ウニヴェルシテ ド モントリオール | 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用 |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| EP4255474A4 (en) * | 2020-12-07 | 2025-06-18 | Iogenetics, LLC. | PERSONALIZED IMMUNOTHERAPIES |
| WO2022147029A2 (en) | 2020-12-31 | 2022-07-07 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| CN113527435B (zh) * | 2021-07-14 | 2022-06-07 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 对前列腺癌细胞特异性识别的新型多肽及其衍生物与应用 |
| WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| JP2025516189A (ja) | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025137979A1 (zh) * | 2023-12-28 | 2025-07-03 | 祺安（广州）生物科技有限公司 | 特异性多肽在制备治疗、预防前列腺癌的药物中的应用 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1037656A (en) | 1911-11-28 | 1912-09-03 | Thomas F Loughran | Prorating-weir. |
| US1178658A (en) | 1914-06-11 | 1916-04-11 | United Shoe Machinery Ab | Gripper mechanism for pulling-over machines. |
| US1165315A (en) | 1914-10-31 | 1915-12-21 | William F Cameron | Governor-valve. |
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IN151589B (enExample) | 1978-12-22 | 1983-05-28 | Biogen Nv | |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| US6037135A (en) | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| US9340577B2 (en) * | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| WO1994020127A1 (en) * | 1993-03-05 | 1994-09-15 | Cytel Corporation | Hla-a2.1 binding peptides and their uses |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| US20040157780A1 (en) * | 1993-11-29 | 2004-08-12 | Epimmune Inc. | CTL inducing peptides from c-erb2 (HER-2/neu) |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US6824993B2 (en) * | 1995-06-06 | 2004-11-30 | Human Genome Sciences, Inc. | Antibodies that bind human prostate specific G-protein receptor HPRAJ70 |
| CA2243235C (en) | 1996-01-17 | 2010-08-10 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| DE19623825C1 (de) | 1996-06-14 | 1998-01-08 | Rottefella As | Langlauf- oder Tourenskibindung |
| WO1998010292A1 (en) * | 1996-09-06 | 1998-03-12 | Centocor, Inc. | Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen |
| US7008772B1 (en) * | 1997-02-25 | 2006-03-07 | Corixa Corporation | Compounds for immunodiagnosis of prostate cancer and methods for their use |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20070020327A1 (en) * | 1998-11-10 | 2007-01-25 | John Fikes | Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
| AU7994200A (en) | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| US7361338B2 (en) * | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
| JP2003528584A (ja) * | 1999-10-07 | 2003-09-30 | シエーリング アクチエンゲゼルシャフト | Ｐｒｏｓｔ０７ポリペプチドをコードするｄｎａ |
| JP2004537252A (ja) * | 1999-11-12 | 2004-12-16 | コリクサ コーポレイション | 前立腺癌の治療及び診断のための組成物及び方法 |
| HUP0203968A3 (en) * | 2000-01-14 | 2004-09-28 | Corixa Corp Seattle | Compositions and methods for the therapy and diagnosis of prostate cancer |
| GB2373500B (en) | 2000-02-04 | 2004-12-15 | Aeomica Inc | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| US20030219806A1 (en) * | 2000-02-22 | 2003-11-27 | Millennium Pharmaceuticals, Inc. | Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor |
| EP1311673A2 (en) | 2000-03-27 | 2003-05-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| DE60142475D1 (de) | 2000-03-27 | 2010-08-12 | Technion Res And Dev Of Founda | Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung |
| JP2003534779A (ja) * | 2000-03-31 | 2003-11-25 | キュラジェン コーポレイション | Ｇタンパク質結合レセプターおよびこのｇタンパク質結合レセプターをコードする核酸 |
| US7834146B2 (en) * | 2000-05-08 | 2010-11-16 | Monsanto Technology Llc | Recombinant polypeptides associated with plants |
| US20030144474A1 (en) | 2000-06-05 | 2003-07-31 | Sunol Molecular Corporation | T cell receptor fusions and conjugates and methods of use thereof |
| GB0015722D0 (en) * | 2000-06-27 | 2000-08-16 | Smithkline Beecham Sa | Vaccine |
| DE60120712T2 (de) * | 2000-08-11 | 2007-07-19 | Mount Sinai Hospital, Toronto | Kallikrein gen |
| ATE536187T1 (de) * | 2000-10-19 | 2011-12-15 | Epimmune Inc | Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen |
| US7048931B1 (en) * | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7459539B2 (en) * | 2000-12-15 | 2008-12-02 | Agensys, Inc. | Antibody that binds zinc transporter protein 108P5H8 |
| AU2002246729A1 (en) * | 2000-12-18 | 2002-08-06 | Curagen Corporation | G-protein coupled receptors and nucleic acids encoding same |
| AUPR402201A0 (en) * | 2001-03-27 | 2001-04-26 | Queensland University Of Technology | Polynucleotides and polypeptides linked to cancer and/or benign tumours |
| CA2458915A1 (en) | 2001-08-31 | 2003-03-13 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| DE10215321A1 (de) * | 2002-04-02 | 2003-10-23 | Metagen Pharmaceuticals Gmbh | Trp-p8 Splice Varianten und regulatorische RNA |
| US7569225B2 (en) * | 2002-08-12 | 2009-08-04 | The Council Of The Queensland Institute Of Medical Research | Immunogenic lipopeptides comprising T-helper and B-cell epitopes |
| US7906620B2 (en) | 2002-08-16 | 2011-03-15 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| EP1578432A4 (en) | 2002-10-03 | 2008-07-30 | Epimmune Inc | HLA BINDING PEPTIDES AND USES THEREOF |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| PT1558643E (pt) | 2002-11-09 | 2009-08-24 | Immunocore Ltd | Apresentação de um receptor das células t |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| GB0318096D0 (en) * | 2003-08-01 | 2003-09-03 | Queen Mary & Westfield College | Vaccine |
| US20050053988A1 (en) | 2003-08-08 | 2005-03-10 | The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Gene expressed in breast cancer and methods of use |
| AU2005328605A1 (en) * | 2005-02-28 | 2006-09-08 | Nycomed Gmbh | Method for identifying PDE11 modulators |
| WO2006098464A1 (ja) * | 2005-03-14 | 2006-09-21 | Link Genomics, Inc. | 前立腺がんの診断方法 |
| PL1760088T3 (pl) | 2005-09-05 | 2008-10-31 | Immatics Biotechnologies Gmbh | Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA) |
| AU2006308863A1 (en) | 2005-10-31 | 2007-05-10 | Janssen Pharmaceutica N.V. | A polypeptide complex of TRPM8 and calmodulin and its uses thereof |
| WO2007132461A2 (en) * | 2006-05-11 | 2007-11-22 | Ramot At Tel Aviv University Ltd. | Classification of protein sequences and uses of classified proteins |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| WO2009135019A2 (en) | 2008-05-01 | 2009-11-05 | Beth Israel Deaconess Medical Center | Methods and compositions for prostate cancer immunotherapy |
| PT2119726E (pt) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| US20110318380A1 (en) | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| WO2010102157A1 (en) | 2009-03-04 | 2010-09-10 | The Regents Of The University Of California | Molecular predictors of biological response to a cenpe inhibitor in cancer |
| EP2550529B1 (en) * | 2010-03-23 | 2021-11-17 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| FR2962655A1 (fr) * | 2010-07-15 | 2012-01-20 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et ses utilisations dans les procedes de traitement des troubles du systeme genito-urinaire |
| US20120121592A1 (en) * | 2010-10-13 | 2012-05-17 | Baylor Research Institute | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells |
| WO2012056407A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| CA2821582A1 (en) * | 2010-12-14 | 2012-06-21 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| CN105163754B (zh) | 2012-09-20 | 2018-01-05 | 王荣福 | 前列腺特异性肿瘤抗原及其用途 |
| ES2603589T3 (es) | 2012-11-08 | 2017-02-28 | F. Hoffmann-La Roche Ag | Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI819228B (zh) | 2013-08-05 | 2023-10-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八） |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| WO2016138362A1 (en) * | 2015-02-26 | 2016-09-01 | The Board Of Trustees Of The University Of Arkansas | Treatment vaccine for prostate cancer |
| WO2016172722A1 (en) * | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201520566D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| US10988754B2 (en) * | 2017-07-04 | 2021-04-27 | Cure Vac AG | Nucleic acid molecules |
| EP4259206A4 (en) | 2020-12-14 | 2025-07-09 | Biontech Us Inc | TISSUE-SPECIFIC ANTIGENS FOR CANCER IMMUNOTHERAPY |
-
2015
- 2015-08-06 GB GBGB1513921.5A patent/GB201513921D0/en not_active Ceased
-
2016
- 2016-08-04 AR ARP160102395A patent/AR105817A1/es not_active Application Discontinuation
- 2016-08-05 CR CR20200434A patent/CR20200434A/es unknown
- 2016-08-05 MY MYPI2020006864A patent/MY200281A/en unknown
- 2016-08-05 TW TW112150529A patent/TW202415673A/zh unknown
- 2016-08-05 JP JP2018505723A patent/JP6884752B2/ja active Active
- 2016-08-05 HU HUE16750766A patent/HUE053657T2/hu unknown
- 2016-08-05 PL PL16750766T patent/PL3331900T3/pl unknown
- 2016-08-05 EP EP20216899.3A patent/EP3854801A3/en active Pending
- 2016-08-05 HR HRP20210709TT patent/HRP20210709T8/hr unknown
- 2016-08-05 SG SG10202001660YA patent/SG10202001660YA/en unknown
- 2016-08-05 PT PT167507664T patent/PT3331900T/pt unknown
- 2016-08-05 TW TW109124889A patent/TW202106702A/zh unknown
- 2016-08-05 BR BR112018001687-0A patent/BR112018001687A2/pt not_active Application Discontinuation
- 2016-08-05 MX MX2018001421A patent/MX2018001421A/es unknown
- 2016-08-05 CA CA2994771A patent/CA2994771C/en active Active
- 2016-08-05 CR CR20200435A patent/CR20200435A/es unknown
- 2016-08-05 MA MA46022A patent/MA46022B1/fr unknown
- 2016-08-05 MA MA41879A patent/MA41879A1/fr unknown
- 2016-08-05 LT LTEP16750766.4T patent/LT3331900T/lt unknown
- 2016-08-05 RS RS20210446A patent/RS61713B1/sr unknown
- 2016-08-05 CR CR20200432A patent/CR20200432A/es unknown
- 2016-08-05 ES ES16750766T patent/ES2862400T3/es active Active
- 2016-08-05 MA MA053452A patent/MA53452A/fr unknown
- 2016-08-05 EP EP23216403.8A patent/EP4324472A3/en active Pending
- 2016-08-05 SI SI201631144T patent/SI3331900T1/sl unknown
- 2016-08-05 US US15/229,970 patent/US9908920B2/en active Active
- 2016-08-05 WO PCT/EP2016/068727 patent/WO2017021527A2/en not_active Ceased
- 2016-08-05 EP EP20216870.4A patent/EP3842446A1/en not_active Withdrawn
- 2016-08-05 CA CA3110640A patent/CA3110640A1/en active Pending
- 2016-08-05 UA UAA201800448A patent/UA125816C2/uk unknown
- 2016-08-05 CR CR20200433A patent/CR20200433A/es unknown
- 2016-08-05 CR CR20180074A patent/CR20180074A/es unknown
- 2016-08-05 AU AU2016303021A patent/AU2016303021B2/en not_active Ceased
- 2016-08-05 CR CR20200431A patent/CR20200431A/es unknown
- 2016-08-05 MY MYPI2020006865A patent/MY203318A/en unknown
- 2016-08-05 CA CA3110633A patent/CA3110633A1/en active Pending
- 2016-08-05 PE PE2018000178A patent/PE20180695A1/es unknown
- 2016-08-05 DK DK16750766.4T patent/DK3331900T3/da active
- 2016-08-05 MY MYPI2018700247A patent/MY202812A/en unknown
- 2016-08-05 EA EA201890440A patent/EA201890440A1/ru unknown
- 2016-08-05 KR KR1020187005514A patent/KR20180035845A/ko not_active Ceased
- 2016-08-05 MA MA053680A patent/MA53680A/fr unknown
- 2016-08-05 PE PE2023002284A patent/PE20250557A1/es unknown
- 2016-08-05 IL IL310078A patent/IL310078A/en unknown
- 2016-08-05 CN CN202111376484.6A patent/CN114395013A/zh active Pending
- 2016-08-05 MD MDE20180586T patent/MD3331900T2/ro unknown
- 2016-08-05 EP EP16750766.4A patent/EP3331900B1/en active Active
- 2016-08-05 TW TW105124943A patent/TWI829618B/zh not_active IP Right Cessation
- 2016-08-05 CN CN201680045204.4A patent/CN107849107A/zh active Pending
-
2017
- 2017-06-29 US US15/637,906 patent/US9993539B2/en active Active
- 2017-06-29 US US15/638,072 patent/US10155032B2/en active Active
- 2017-12-21 US US15/849,878 patent/US10500259B2/en active Active
-
2018
- 2018-01-24 ZA ZA2018/00513A patent/ZA201800513B/en unknown
- 2018-01-25 PH PH12018500189A patent/PH12018500189A1/en unknown
- 2018-02-01 MX MX2021015933A patent/MX2021015933A/es unknown
- 2018-02-04 IL IL257331A patent/IL257331A/en unknown
- 2018-02-05 CL CL2018000324A patent/CL2018000324A1/es unknown
- 2018-02-27 CO CONC2018/0002202A patent/CO2018002202A2/es unknown
- 2018-08-10 US US16/100,498 patent/US10383930B2/en active Active
- 2018-10-05 US US16/153,294 patent/US10238727B2/en active Active
- 2018-12-05 US US16/210,330 patent/US10376568B2/en active Active
-
2019
- 2019-04-16 US US16/385,221 patent/US10449238B2/en active Active
- 2019-04-16 US US16/385,225 patent/US10478480B2/en active Active
- 2019-07-10 US US16/507,375 patent/US10532091B1/en active Active
- 2019-08-27 US US16/552,873 patent/US10799569B2/en active Active
-
2020
- 2020-06-29 US US16/915,465 patent/US11058754B2/en active Active
- 2020-09-10 US US17/017,281 patent/US11065315B2/en not_active Expired - Fee Related
- 2020-11-18 JP JP2020191407A patent/JP7142957B2/ja active Active
-
2021
- 2021-02-26 CY CY20211100164T patent/CY1123854T1/el unknown
- 2021-04-01 AU AU2021202057A patent/AU2021202057B2/en not_active Ceased
- 2021-04-01 AU AU2021202059A patent/AU2021202059B2/en not_active Ceased
- 2021-04-01 AU AU2021202060A patent/AU2021202060B2/en not_active Ceased
- 2021-04-01 AU AU2021202058A patent/AU2021202058B2/en not_active Ceased
- 2021-04-01 AU AU2021202056A patent/AU2021202056B2/en not_active Ceased
- 2021-05-14 US US17/320,878 patent/US20210275653A1/en not_active Abandoned
- 2021-05-14 US US17/320,938 patent/US11826409B2/en active Active
- 2021-05-14 US US17/320,929 patent/US11786584B2/en active Active
- 2021-06-11 CL CL2021001542A patent/CL2021001542A1/es unknown
- 2021-06-11 CL CL2021001545A patent/CL2021001545A1/es unknown
- 2021-06-11 CL CL2021001543A patent/CL2021001543A1/es unknown
- 2021-06-11 CL CL2021001544A patent/CL2021001544A1/es unknown
- 2021-06-30 CL CL2021001744A patent/CL2021001744A1/es unknown
-
2022
- 2022-01-14 US US17/576,067 patent/US12102670B2/en active Active
- 2022-01-14 US US17/576,185 patent/US12076381B2/en active Active
- 2022-01-21 US US17/581,049 patent/US12097249B2/en active Active
- 2022-01-21 US US17/581,054 patent/US20220143163A1/en not_active Abandoned
- 2022-01-28 US US17/587,536 patent/US12144852B2/en active Active
- 2022-01-28 US US17/587,474 patent/US12180259B2/en active Active
- 2022-02-04 US US17/592,573 patent/US20220152175A1/en not_active Abandoned
- 2022-09-07 JP JP2022142129A patent/JP2022191218A/ja active Pending
- 2022-11-21 CL CL2022003264A patent/CL2022003264A1/es unknown
-
2023
- 2023-07-13 AU AU2023204661A patent/AU2023204661A1/en not_active Abandoned
- 2023-08-17 US US18/451,216 patent/US20240016908A1/en active Pending
- 2023-09-22 AU AU2023233214A patent/AU2023233214A1/en not_active Abandoned
-
2024
- 2024-12-10 JP JP2024215091A patent/JP2025038025A/ja active Pending